Multiple Myeloma Patient Registry in Germany

This study is a comprehensive registry focused on multiple myeloma, a type of blood cancer, in Germany. It is organized by the German-speaking Myeloma Multicenter Group (GMMG) and gathers data from patients across 35 centers. The registry aims to collect information about patients' diagnoses, treatments, and long-term outcomes to improve understanding of multiple myeloma. It includes data from both past and ongoing studies, such as a trial that evaluated the effectiveness of adding a specific antibody, elotuzumab, to standard therapy for those eligible for a stem cell transplant. By analyzing this information, the registry seeks to enhance treatment strategies and improve survival rates for patients. Participants in the registry are monitored throughout their treatment until they pass away, lose contact, or decide to leave the study. Information about their health is collected every six months, and after the first signs of disease progression, it is updated annually. The study looks at important factors like how long patients live without the cancer worsening and overall survival rates. Data is managed confidentially using a secured system, with regular checks to ensure accuracy. The registry does not involve any new treatments or interventions, focusing solely on observing and recording patients' experiences with the standard care they receive.